Emerging Markets Earnings: China A Star For Merck Key Product Sales
This article was originally published in PharmAsia News
Executive Summary
Merck looks for growth in key products across emerging markets to keep full-year earnings in check even as it revises down its forecast for revenues.
You may also be interested in...
As Merck’s Keytruda Gains Momentum, Investors Look To The Future
Keytruda, already the first anti-PD-1 drug to market for melanoma, received FDA breakthrough therapy designation for an indication in lung cancer. The drug’s long-term potential – and upcoming data on a two-drug hepatitis C combo – helped to offset a decline in Merck’s third quarter sales.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.